Stock Track | GenScript Bio Soars 5.57% Intraday on ASCO Data Releases and Valuation Sentiment

Stock Track05-27

GenScript Bio's stock soared 5.57% during intraday trading on Wednesday, driven by positive developments from its associate company and market sentiment around valuation.

The surge follows news that Legend Biotech, in which GenScript holds a significant stake, will present multiple research results at the upcoming ASCO Annual Meeting. This includes Phase 1 preliminary data for LB2102, an investigational DLL3-targeting CAR-T therapy targeting relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma, along with new CARVYKTI data disclosures.

Market analysts note that the expansion of CAR-T therapy into solid tumor indications represents significant growth potential for GenScript. Additionally, discussions about GenScript's valuation inversion—where its total market capitalization remains below the value of its stake in Legend Biotech—have supported short-term sentiment recovery, contributing to the stock's rebound.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196637242?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 09:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196637242","market":"sg","top_or_hot":-1,"title":"Stock Track | GenScript Bio Soars 5.57% Intraday on ASCO Data Releases and Valuation Sentiment","media":"Stock Track","content":"<p>GenScript Bio's stock soared 5.57% during intraday trading on Wednesday, driven by positive developments from its associate company and market sentiment around valuation.</p><p>The surge follows news that Legend Biotech, in which GenScript holds a significant stake, will present multiple research results at the upcoming ASCO Annual Meeting. This includes Phase 1 preliminary data for LB2102, an investigational DLL3-targeting CAR-T therapy targeting relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma, along with new CARVYKTI data disclosures.</p><p>Market analysts note that the expansion of CAR-T therapy into solid tumor indications represents significant growth potential for GenScript. Additionally, discussions about GenScript's valuation inversion—where its total market capitalization remains below the value of its stake in Legend Biotech—have supported short-term sentiment recovery, contributing to the stock's rebound.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GenScript Bio Soars 5.57% Intraday on ASCO Data Releases and Valuation Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GenScript Bio Soars 5.57% Intraday on ASCO Data Releases and Valuation Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-27 09:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GenScript Bio's stock soared 5.57% during intraday trading on Wednesday, driven by positive developments from its associate company and market sentiment around valuation.</p><p>The surge follows news that Legend Biotech, in which GenScript holds a significant stake, will present multiple research results at the upcoming ASCO Annual Meeting. This includes Phase 1 preliminary data for LB2102, an investigational DLL3-targeting CAR-T therapy targeting relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma, along with new CARVYKTI data disclosures.</p><p>Market analysts note that the expansion of CAR-T therapy into solid tumor indications represents significant growth potential for GenScript. Additionally, discussions about GenScript's valuation inversion—where its total market capitalization remains below the value of its stake in Legend Biotech—have supported short-term sentiment recovery, contributing to the stock's rebound.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1196637242","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196637242","pubTimestamp":1779846865,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GenScript Bio's stock soared 5.57% during intraday trading on Wednesday, driven by positive developments from its associate company and market sentiment around valuation.The surge follows news that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"个股追踪|金斯瑞生物盘中大涨5.57%受ASCO数据公布及估值情绪影响","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"GenScript Bio's stock soared 5.57% during intraday trading on Wednesday, driven by positive developments from its associate company and market sentiment around valuation.The surge follows news that Legend Biotech, in which GenScript holds a significant stake, will present multiple research results at the upcoming ASCO Annual Meeting. This includes Phase 1 preliminary data for LB2102, an investigational DLL3-targeting CAR-T therapy targeting relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma, along with new CARVYKTI data disclosures.Market analysts note that the expansion of CAR-T therapy into solid tumor indications represents significant growth potential for GenScript. Additionally, discussions about GenScript's valuation inversion—where its total market capitalization remains below the value of its stake in Legend Biotech—have supported short-term sentiment recovery, contributing to the stock's rebound.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196637242","isCrawlerRequest":true}